Metabolic tumor volume assessed by18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma

Rosa Fonti, Michele Larobina, Silvana Del Vecchio, Serena De Luca, Rossella Fabbricini, Lucio Catalano, Fabrizio Pane, Marco Salvatore, Leonardo Pace

Research output: Contribution to journalArticle

Abstract

18F-FDG PET/CT allows the direct measurement of metabolic tumor burden in a variety of different malignancies. The aim of this study was to assess whether metabolic tumor volume (MTV) determined by 18F-FDG PET/CT could be used in the prediction of progression-free and overall survival in multiple myeloma patients. Methods: Forty-seven patients (18 women, 29 men; mean age ± SD, 63 ± 11 y) with stage IIIA disease who had undergone whole-body 18F-FDG PET/CT were retrospectively evaluated. Images underwent a 3-dimensional region-of-interest analysis including all focal lesions with a maximum standardized uptake value > 2.5. The MTV of each lesion was calculated using an automated contouring program based on the standardized uptake value and developed with a threshold of 40% of the maximum standardized uptake value. The total MTV of each patient was defined as the sum of metabolic volume of all focal lesions. Patients were treated and then subjected to a mean follow-up period of 24 mo. Results: In the 47 patients studied, MTV range was 1.3-316.3 mL, with a median of 23.7 mL. A direct, significant correlation was found between MTV and the percentage of diffuse infiltration of bone marrow by plasma cells (r = 0.46, P = 0.006), whereas hemoglobin levels were inversely correlated with MTV (r = 20.56, P = 0.0001). At follow-up, patients who developed progressive disease (n = 18) showed a significantly higher MTV (74.7 ± 19.3 vs. 29.8 ± 5.1 mL, P = 0.009) than patients without progressive disease (n = 29). Furthermore, patients who died of myeloma (n = 9) had a significantly higher MTV (123.2 ± 30.6 vs. 28.9 ± 4.2 mL, P = 0.0001) than survivors (n = 38). No differences in age, plasma cell infiltration, M protein, albumin, β2-microglobulin, performance status, International Staging System score, and presence or absence of a bone marrow transplant were found between groups. The MTV cutoff level was determined by receiver-operating-characteristic curve analysis, and the best discriminative value found for predicting progression-free and overall survival was 42.2 and 77.6 mL, respectively. By Kaplan-Meier analysis and log-rank testing, progression-free and overall survival at follow-up were significantly better in patients showing an MTV lower than the cutoff than in those having an MTV higher than the cutoff (χ2 = 3.9, P = 0.04, and χ2 = 56.3, P <0.0001, respectively). Conclusion: The direct measurement of tumor burden obtained by calculating MTV on 18F-FDG PET/CT images may be used in the prediction of progression-free and overall survival in myeloma patients.

Original languageEnglish
Pages (from-to)1829-1835
Number of pages7
JournalJournal of Nuclear Medicine
Volume53
Issue number12
DOIs
Publication statusPublished - Dec 1 2012

Keywords

  • F-FDG-PET/CT
  • Metabolic tumor volume
  • Multiple myeloma
  • Prognosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Metabolic tumor volume assessed by18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Fonti, R., Larobina, M., Del Vecchio, S., De Luca, S., Fabbricini, R., Catalano, L., Pane, F., Salvatore, M., & Pace, L. (2012). Metabolic tumor volume assessed by18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. Journal of Nuclear Medicine, 53(12), 1829-1835. https://doi.org/10.2967/jnumed.112.106500